Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan.
Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Miyake H, et al. Among authors: ozono s. Clin Genitourin Cancer. 2017 Apr;15(2):313-319. doi: 10.1016/j.clgc.2016.06.010. Epub 2016 Jun 23. Clin Genitourin Cancer. 2017. PMID: 27424256
Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Among authors: ozono s. Clin Genitourin Cancer. 2017 Aug;15(4):e591-e597. doi: 10.1016/j.clgc.2016.12.015. Epub 2016 Dec 22. Clin Genitourin Cancer. 2017. PMID: 28063845
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Among authors: ozono s. Urol Oncol. 2017 Jun;35(6):432-437. doi: 10.1016/j.urolonc.2017.01.006. Epub 2017 Feb 8. Urol Oncol. 2017. PMID: 28188090
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Suzuki H, et al. Among authors: ozono s. J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635218
437 results